Investors & Media

The investor relations section of Selvita S.A. is addressed to all capital market participants and media, and in particular to our shareholders, analysts, individual and institutional investors interested in our company.

You’ll be able to find here the latest information on our financial results, current operations and development plans, as well as a range of other useful information. If there is anything more you should need, don’t hesitate to contact us!

Investors & Media

Overview

Selvita share price [PLN]

News feed

Selvita as an Innovation Partner of the Inaugural European Targeted Protein Degradation Summit
13 February 2020

Selvita as an Innovation Partner of the Inaugural European Targeted Protein Degradation Summit

Continue reading
Selvita to Exhibit at the North American Protein Degradation Congress in San Diego
23 January 2020

Selvita to Exhibit at the North American Protein Degradation Congress in San Diego

Continue reading
Selvita Open Days
08 January 2020

Selvita Open Days

Continue reading

Reports

Show
  • 07 November 2019

    Raport ESPI SA-Q 3/2019

    Selvita S.A. Quarterly Report 2019 Q3 (Summary)

Financial results

PLN 55 356 022 73 233 124
PLN 7 769 051 8 325 269
PLN 11 286 217 16 487 113
PLN 8 276 192 7 981 042

* Presented data show the financial results achieved by the Separated Part (CRO) in the period from 01/01/2018 to 30/09/2018 and demonstrate how the Selvita S.A. Group financial data would look like if the corporate split had happened on January 1, 2018.

** Revenues from sales + revenues from grants + remaining operating revenues

Shareholder structure

Share in capital
Share in votes
Shareholder Share in capital Share in votes
Paweł Przewięźlikowski
Bogusław Sieczkowski
Augebit FIZ*
Nationale Nederlanden OFE
Remaining Management Board and Supervisory Board Members
Remaining Shareholders
* the beneficiary of Augebit FIZ is Tadeusz Wesołowski – Vice Chairman of Selvita Supervisory Board; information based on the number of shares from the last notification provided by the shareholder to the Company (without taking into account the dilution resulting from the issue of H shares).

Events & Presentations

  • 01-05 March 2020
    Pittcon 2020 - Chicago, IL, US
  • 06 March 2020
    French Industrial Chemistry Symposium (FICS) - Paris, France
  • 17-19 March 2020
    Inaugural European Targeted Protein Degradation Summit - London, UK
  • 22-25 March 2020
    Frontiers in Medicinal Chemistry - Freiburg, Germany
  • 23-25 March 2020
    BIO Europe Spring - Paris, France
  • 25-26 March 2020
    State of Possible Conference: MassBio's Annual Meeting - Cambridge, MA, US
  • 27 March 2020
    Synthesis in Drug Discovery and Development -
    Lilly Research Centre, Windlesham, Surrey, UK
  • 31-01 April 2020
    2020 ELRIG Research & Innovation - Oxford, UK
  • 02-03 April 2020
    5th Drug Discovery Strategic Summit - Boston, US
  • 07-08 April 2020
    2020 Life Science Innovation Northwest - Washington, US
  • 13-17 April 2020
    CHI’s 15th Annual Drug Discovery Chemistry - San Diego, CA, US
  • 30 April 2020
    31st Symposium on Medicinal Chemistry in Eastern England
  • 01-02 June 2020
    Kinase 2020: 9th RSC / SCI symposium on kinase inhibitor design -
    The Francis Crick Institute, London, UK
selvita_logo

Contacts